Clinical Trial Update: Phase I Study of mPEG-R-Crisantaspase Given IV [Phase 1]

View source ↗

Summary

Phase I intravenous study of mPEG-R-Crisantaspase for hematologic malignancies, sponsored by Jazz Pharmaceuticals, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• mPEG-R-Crisantaspase (crisantaspase)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Hematologic Malignancies | Phase 1 | Status: COMPLETED